Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)

BACKGROUND: Despite the prolonged median disease-free survival (DFS) by adjuvant targeted therapy in non-small-cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations, the relationship between the treatment duration and the survival benefits in patients remains unknown. PATI...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, C., Wang, R., Li, S., Yan, S., Wang, Y., Chen, J., Wang, L., Liu, Y., Guo, Z., Wang, J., Pei, Y., Yu, L., Wu, N., Lu, F., Gao, F., Wang, X., Han, B., Zhang, L., Ma, Y., Ding, L., Yuan, X., Yang, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515286/
https://www.ncbi.nlm.nih.gov/pubmed/37348348
http://dx.doi.org/10.1016/j.esmoop.2023.101565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515286/
https://www.ncbi.nlm.nih.gov/pubmed/37348348
http://dx.doi.org/10.1016/j.esmoop.2023.101565

Ejemplares similares